J&J said in a statement that it was "assuming full responsibility regarding the manufacturing of drug substance for its COVID-19 vaccine at the Emergent BioSolutions Inc. Bayview facility."
The U.S. government on Saturday stopped a Baltimore manufacturing plant that ruined 15 million doses of 
Johnson & 
Johnson's 
COVID-19 
vaccine from making the 
vaccine developed by 
AstraZeneca Plc, the New York Times reported.
J&J said in a statement that it was "assuming full responsibility regarding the manufacturing of drug substance for its 
COVID-19 
vaccine at the Emergent BioSolutions Inc. Bayview facility."
It did not specify if it will take over the plant. The company did not respond to Reuters' requests for comment for clarification.
The New York Times reported that 
AstraZeneca said in a statement it will work with President 
Joe Biden's administration to find an alternative site. The drugmaker did not respond to a request for comment.
The move by the U.S. Department of Health and Human Services' will render the Emergent BioSolutions facility solely devoted to making the 
Johnson & 
Johnson single-dose 
vaccine, and is meant to avoid future mix-ups, according to the newspaper report, which cites two senior federal health official
The U.S. government's top infectious disease doctor told Reuters the country may not need 
AstraZeneca's 
vaccine, even if it wins approval.